Compare OPLN & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPLN | IMNM |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | OPLN | IMNM |
|---|---|---|
| Price | $29.66 | $21.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $32.00 | ★ $32.80 |
| AVG Volume (30 Days) | 807.6K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | $8.66 | N/A |
| Revenue Next Year | $6.14 | $1,127.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.81 | $6.97 |
| 52 Week High | $31.78 | $27.65 |
| Indicator | OPLN | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 62.12 | 52.34 |
| Support Level | $29.48 | $19.23 |
| Resistance Level | $31.55 | $22.86 |
| Average True Range (ATR) | 0.71 | 1.13 |
| MACD | 0.29 | 0.23 |
| Stochastic Oscillator | 77.75 | 64.57 |
Openlane Inc provides a digital marketplace for used vehicles, connecting sellers and buyers in North America and Europe for fast and transparent transactions. Its services include financing, repossessions, repairs, transportation, warranty, and inventory management. The company operates used-vehicle auctions and has two main segments: Marketplace and Finance, with majority revenue coming from the Marketplace segment, which to used vehicle remarketing, including marketplace services, remarketing, or make ready services and all are interrelated, synergistic elements along the auto remarketing chain. The Finance segment, through AFC engaged in business of providing short-term, inventory-secured financing to independent vehicle dealers.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.